Yahoo
Taipei Exchange - Delayed Quote TWD

Universal Vision Biotechnology Co., Ltd. (3218.TWO)

129.50 -1.50 (-1.15%)
At close: October 30 at 1:30:14 PM GMT+8
Chart Range Bar
Loading chart for 3218.TWO
  • Previous Close 131.00
  • Open 131.00
  • Bid 129.00 x --
  • Ask 129.50 x --
  • Day's Range 128.50 - 131.00
  • 52 Week Range 122.00 - 161.00
  • Volume 184,594
  • Avg. Volume 180,485
  • Market Cap (intraday) 10.972B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 9.62
  • EPS (TTM) 13.46
  • Earnings Date (est.) --
  • Forward Dividend & Yield 7.75 (5.98%)
  • Ex-Dividend Date Mar 26, 2026
  • 1y Target Est 150.00

Universal Vision Biotechnology Co., Ltd., a biotech company, provides vision care services in Taiwan and China. The company offers various glasses and lenses for vision correction, contact lens solutions, and related eye care products; equipment rental and technical services for laser vision correction instruments; and technology and services for cataract and dry eye examination and treatment instruments. It also trades in medical and pharmaceutical consumables, including ophthalmic drugs, medical supplies, and consumables; and provides administrative and other professional logistics support services for cooperative clinics and eye centers, as well as brand licensing and consulting services. The company offers its products through its self-operated eyeglasses stores. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.

www.uvb.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

3218.TWO
6.04%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
56.10%

1-Year Return

3218.TWO
3.74%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
59.83%

3-Year Return

3218.TWO
52.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
179.95%

5-Year Return

3218.TWO
47.07%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
166.15%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.13B
Earnings 226.46M
Profit Margin 20.10%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
1B
25.0%
30.0%

Analyst Insights

View More

Analyst Price Targets

150.00
150.00 Average
129.50 Current
150.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.78%

  • Return on Assets (ttm)

    13.81%

  • Return on Equity (ttm)

    31.24%

  • Revenue (ttm)

    4.27B

  • Net Income Avi to Common (ttm)

    1.14B

  • Diluted EPS (ttm)

    13.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.03B

  • Total Debt/Equity (mrq)

    38.62%

  • Levered Free Cash Flow (ttm)

    1.04B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: